Skip to main content
main-content

02-06-2019 | Breast cancer | Video

ASCO 2019: Ribociclib addition boosts OS in premenopausal advanced breast cancer patients

Sara Hurvitz summarises the findings of the phase III MONALEESA-7 trial investigating the addition of ribociclib to endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer (3:21).

Funding for independent interviews at ASCO 2019 was provided in part by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits